Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study
Objective: To describe the efficacy and safety of adalimumab in patients with rheumatoid arthritis (RA) who had previously discontinued infliximab treatment. Methods: 24 patients with RA who discontinued treatment with infliximab (switchers) were treated with adalimumab (40 mg every 2 weeks, subcuta...
Gespeichert in:
| Veröffentlicht in: | Annals of the rheumatic diseases 2006-02, Vol.65 (2), p.257-260 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 260 |
|---|---|
| container_issue | 2 |
| container_start_page | 257 |
| container_title | Annals of the rheumatic diseases |
| container_volume | 65 |
| creator | Nikas, S N Voulgari, P V Alamanos, Y Papadopoulos, C G Venetsanopoulou, A I Georgiadis, A N Drosos, A A |
| description | Objective: To describe the efficacy and safety of adalimumab in patients with rheumatoid arthritis (RA) who had previously discontinued infliximab treatment. Methods: 24 patients with RA who discontinued treatment with infliximab (switchers) were treated with adalimumab (40 mg every 2 weeks, subcutaneously) for 12 months. The results were compared with those for 25 patients with RA receiving adalimumab who had not previously used an anti-tumour necrosis factor α inhibitor (controls). Disease activity was measured with the 28 joint count Disease Activity Score (DAS28), and clinical response with the American College of Rheumatology (ACR) 20% response criteria. Results: At baseline there were no differences in demographic, clinical, and laboratory features between the two groups. After 12 months’ adalimumab treatment, clinical improvement was similar in both groups. More specifically, ACR 20% response criteria were achieved by 18/24 (75%) switchers and by 19/25 (76%) subjects in the control group. Four switchers discontinued the study—two because of adverse events and two because of lack of efficacy, while three control patients discontinued the study—one because of lack of efficacy and two owing to side effects. Conclusion: Adalimumab is a well tolerated and effective treatment for patients with RA, even when infliximab has been discontinued. |
| doi_str_mv | 10.1136/ard.2005.039099 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1798023</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4008379771</sourcerecordid><originalsourceid>FETCH-LOGICAL-b522t-3ad873192bc1f4cce7c26119683d4ccc2c1f30ecc99322897bb4dbf456feabe93</originalsourceid><addsrcrecordid>eNqFkc1v1DAQxS0EokvhzA1ZQnBAytZfsWMOSGhVvlTBpZQb1sSxWy9JvNhJ6f73eLWrFrhwsmfm56c3fgg9pWRJKZcnkLolI6ReEq6J1vfQggrZVIxIch8tCCG8ElqqI_Qo53UpSUObh-iI1lrVWooF-n7qfbBgtxjGDmfwbtri6HH-FSZ7FcZL7FMccBh9H27CAC2eIoYO-jDMpXqNAds4bCDBFK5duY9Tin3vitY0d9vH6IGHPrsnh_MYfX13er76UJ19ef9x9fasamvGpopD1yhONWst9cJapyyTlGrZ8K6UlpU2J85arTljjVZtK7rWi1p6B63T_Bi92etu5nZwnXXFBvRmk4rltDURgvl7MoYrcxmvDVW6IYwXgZcHgRR_zi5PZgjZur6H0cU5G0Vk-TpeF_D5P-A6zmksyxUtpRrRCLHzc7KnbIo5J-dvrVBidsmZkpzZJWf2yZUXz_7c4I4_RFWAFwcAsoXeJxhtyHecElwwxQpX7bmQJ3dzO4f0w0jFVW0-X6zMp3N1Qb_plVGFf7Xn22H9X5e_AXhCv5M</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1777848449</pqid></control><display><type>article</type><title>Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study</title><source>MEDLINE</source><source>BMJ Journals - NESLi2</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Nikas, S N ; Voulgari, P V ; Alamanos, Y ; Papadopoulos, C G ; Venetsanopoulou, A I ; Georgiadis, A N ; Drosos, A A</creator><creatorcontrib>Nikas, S N ; Voulgari, P V ; Alamanos, Y ; Papadopoulos, C G ; Venetsanopoulou, A I ; Georgiadis, A N ; Drosos, A A</creatorcontrib><description>Objective: To describe the efficacy and safety of adalimumab in patients with rheumatoid arthritis (RA) who had previously discontinued infliximab treatment. Methods: 24 patients with RA who discontinued treatment with infliximab (switchers) were treated with adalimumab (40 mg every 2 weeks, subcutaneously) for 12 months. The results were compared with those for 25 patients with RA receiving adalimumab who had not previously used an anti-tumour necrosis factor α inhibitor (controls). Disease activity was measured with the 28 joint count Disease Activity Score (DAS28), and clinical response with the American College of Rheumatology (ACR) 20% response criteria. Results: At baseline there were no differences in demographic, clinical, and laboratory features between the two groups. After 12 months’ adalimumab treatment, clinical improvement was similar in both groups. More specifically, ACR 20% response criteria were achieved by 18/24 (75%) switchers and by 19/25 (76%) subjects in the control group. Four switchers discontinued the study—two because of adverse events and two because of lack of efficacy, while three control patients discontinued the study—one because of lack of efficacy and two owing to side effects. Conclusion: Adalimumab is a well tolerated and effective treatment for patients with RA, even when infliximab has been discontinued.</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/ard.2005.039099</identifier><identifier>PMID: 15975964</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><subject>28 joint count Disease Activity Score ; ACR ; Adalimumab ; Age ; Aged ; American College of Rheumatology ; Antibodies, Monoclonal - administration & dosage ; Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized ; Antirheumatic Agents - administration & dosage ; Antirheumatic Agents - adverse effects ; Antirheumatic Agents - therapeutic use ; Arthritis, Rheumatoid - drug therapy ; Arthritis, Rheumatoid - immunology ; Arthritis, Rheumatoid - physiopathology ; Biological and medical sciences ; Blood Sedimentation ; C-Reactive Protein - analysis ; Concise Report ; Crohn's disease ; DAS 28 ; Diseases of the osteoarticular system ; Drug Administration Schedule ; Drug dosages ; Female ; Health Status Indicators ; Humans ; Immunomodulators ; Infliximab ; Joints - physiopathology ; Male ; Medical sciences ; methotrexate ; Middle Aged ; MTX ; Pharmacology. Drug treatments ; Platelet Count ; Rheumatism ; rheumatoid arthritis ; TNFα ; Treatment Outcome ; Tumor Necrosis Factor-alpha - antagonists & inhibitors ; tumour necrosis factor α</subject><ispartof>Annals of the rheumatic diseases, 2006-02, Vol.65 (2), p.257-260</ispartof><rights>Copyright 2006 by Annals of the Rheumatic Diseases</rights><rights>2006 INIST-CNRS</rights><rights>Copyright: 2006 Copyright 2006 by Annals of the Rheumatic Diseases</rights><rights>Copyright © 2006 BMJ Publishing Group Ltd & European League Against Rheumatism</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b522t-3ad873192bc1f4cce7c26119683d4ccc2c1f30ecc99322897bb4dbf456feabe93</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/65/2/257.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/65/2/257.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,230,314,727,780,784,885,3196,23571,27924,27925,53791,53793,77600,77631</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17434272$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15975964$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nikas, S N</creatorcontrib><creatorcontrib>Voulgari, P V</creatorcontrib><creatorcontrib>Alamanos, Y</creatorcontrib><creatorcontrib>Papadopoulos, C G</creatorcontrib><creatorcontrib>Venetsanopoulou, A I</creatorcontrib><creatorcontrib>Georgiadis, A N</creatorcontrib><creatorcontrib>Drosos, A A</creatorcontrib><title>Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study</title><title>Annals of the rheumatic diseases</title><addtitle>Ann Rheum Dis</addtitle><description>Objective: To describe the efficacy and safety of adalimumab in patients with rheumatoid arthritis (RA) who had previously discontinued infliximab treatment. Methods: 24 patients with RA who discontinued treatment with infliximab (switchers) were treated with adalimumab (40 mg every 2 weeks, subcutaneously) for 12 months. The results were compared with those for 25 patients with RA receiving adalimumab who had not previously used an anti-tumour necrosis factor α inhibitor (controls). Disease activity was measured with the 28 joint count Disease Activity Score (DAS28), and clinical response with the American College of Rheumatology (ACR) 20% response criteria. Results: At baseline there were no differences in demographic, clinical, and laboratory features between the two groups. After 12 months’ adalimumab treatment, clinical improvement was similar in both groups. More specifically, ACR 20% response criteria were achieved by 18/24 (75%) switchers and by 19/25 (76%) subjects in the control group. Four switchers discontinued the study—two because of adverse events and two because of lack of efficacy, while three control patients discontinued the study—one because of lack of efficacy and two owing to side effects. Conclusion: Adalimumab is a well tolerated and effective treatment for patients with RA, even when infliximab has been discontinued.</description><subject>28 joint count Disease Activity Score</subject><subject>ACR</subject><subject>Adalimumab</subject><subject>Age</subject><subject>Aged</subject><subject>American College of Rheumatology</subject><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Antirheumatic Agents - administration & dosage</subject><subject>Antirheumatic Agents - adverse effects</subject><subject>Antirheumatic Agents - therapeutic use</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Arthritis, Rheumatoid - immunology</subject><subject>Arthritis, Rheumatoid - physiopathology</subject><subject>Biological and medical sciences</subject><subject>Blood Sedimentation</subject><subject>C-Reactive Protein - analysis</subject><subject>Concise Report</subject><subject>Crohn's disease</subject><subject>DAS 28</subject><subject>Diseases of the osteoarticular system</subject><subject>Drug Administration Schedule</subject><subject>Drug dosages</subject><subject>Female</subject><subject>Health Status Indicators</subject><subject>Humans</subject><subject>Immunomodulators</subject><subject>Infliximab</subject><subject>Joints - physiopathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>methotrexate</subject><subject>Middle Aged</subject><subject>MTX</subject><subject>Pharmacology. Drug treatments</subject><subject>Platelet Count</subject><subject>Rheumatism</subject><subject>rheumatoid arthritis</subject><subject>TNFα</subject><subject>Treatment Outcome</subject><subject>Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><subject>tumour necrosis factor α</subject><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFkc1v1DAQxS0EokvhzA1ZQnBAytZfsWMOSGhVvlTBpZQb1sSxWy9JvNhJ6f73eLWrFrhwsmfm56c3fgg9pWRJKZcnkLolI6ReEq6J1vfQggrZVIxIch8tCCG8ElqqI_Qo53UpSUObh-iI1lrVWooF-n7qfbBgtxjGDmfwbtri6HH-FSZ7FcZL7FMccBh9H27CAC2eIoYO-jDMpXqNAds4bCDBFK5duY9Tin3vitY0d9vH6IGHPrsnh_MYfX13er76UJ19ef9x9fasamvGpopD1yhONWst9cJapyyTlGrZ8K6UlpU2J85arTljjVZtK7rWi1p6B63T_Bi92etu5nZwnXXFBvRmk4rltDURgvl7MoYrcxmvDVW6IYwXgZcHgRR_zi5PZgjZur6H0cU5G0Vk-TpeF_D5P-A6zmksyxUtpRrRCLHzc7KnbIo5J-dvrVBidsmZkpzZJWf2yZUXz_7c4I4_RFWAFwcAsoXeJxhtyHecElwwxQpX7bmQJ3dzO4f0w0jFVW0-X6zMp3N1Qb_plVGFf7Xn22H9X5e_AXhCv5M</recordid><startdate>20060201</startdate><enddate>20060201</enddate><creator>Nikas, S N</creator><creator>Voulgari, P V</creator><creator>Alamanos, Y</creator><creator>Papadopoulos, C G</creator><creator>Venetsanopoulou, A I</creator><creator>Georgiadis, A N</creator><creator>Drosos, A A</creator><general>BMJ Publishing Group Ltd and European League Against Rheumatism</general><general>BMJ</general><general>BMJ Publishing Group LTD</general><general>BMJ Group</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20060201</creationdate><title>Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study</title><author>Nikas, S N ; Voulgari, P V ; Alamanos, Y ; Papadopoulos, C G ; Venetsanopoulou, A I ; Georgiadis, A N ; Drosos, A A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b522t-3ad873192bc1f4cce7c26119683d4ccc2c1f30ecc99322897bb4dbf456feabe93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>28 joint count Disease Activity Score</topic><topic>ACR</topic><topic>Adalimumab</topic><topic>Age</topic><topic>Aged</topic><topic>American College of Rheumatology</topic><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Antirheumatic Agents - administration & dosage</topic><topic>Antirheumatic Agents - adverse effects</topic><topic>Antirheumatic Agents - therapeutic use</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Arthritis, Rheumatoid - immunology</topic><topic>Arthritis, Rheumatoid - physiopathology</topic><topic>Biological and medical sciences</topic><topic>Blood Sedimentation</topic><topic>C-Reactive Protein - analysis</topic><topic>Concise Report</topic><topic>Crohn's disease</topic><topic>DAS 28</topic><topic>Diseases of the osteoarticular system</topic><topic>Drug Administration Schedule</topic><topic>Drug dosages</topic><topic>Female</topic><topic>Health Status Indicators</topic><topic>Humans</topic><topic>Immunomodulators</topic><topic>Infliximab</topic><topic>Joints - physiopathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>methotrexate</topic><topic>Middle Aged</topic><topic>MTX</topic><topic>Pharmacology. Drug treatments</topic><topic>Platelet Count</topic><topic>Rheumatism</topic><topic>rheumatoid arthritis</topic><topic>TNFα</topic><topic>Treatment Outcome</topic><topic>Tumor Necrosis Factor-alpha - antagonists & inhibitors</topic><topic>tumour necrosis factor α</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nikas, S N</creatorcontrib><creatorcontrib>Voulgari, P V</creatorcontrib><creatorcontrib>Alamanos, Y</creatorcontrib><creatorcontrib>Papadopoulos, C G</creatorcontrib><creatorcontrib>Venetsanopoulou, A I</creatorcontrib><creatorcontrib>Georgiadis, A N</creatorcontrib><creatorcontrib>Drosos, A A</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nikas, S N</au><au>Voulgari, P V</au><au>Alamanos, Y</au><au>Papadopoulos, C G</au><au>Venetsanopoulou, A I</au><au>Georgiadis, A N</au><au>Drosos, A A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study</atitle><jtitle>Annals of the rheumatic diseases</jtitle><addtitle>Ann Rheum Dis</addtitle><date>2006-02-01</date><risdate>2006</risdate><volume>65</volume><issue>2</issue><spage>257</spage><epage>260</epage><pages>257-260</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>Objective: To describe the efficacy and safety of adalimumab in patients with rheumatoid arthritis (RA) who had previously discontinued infliximab treatment. Methods: 24 patients with RA who discontinued treatment with infliximab (switchers) were treated with adalimumab (40 mg every 2 weeks, subcutaneously) for 12 months. The results were compared with those for 25 patients with RA receiving adalimumab who had not previously used an anti-tumour necrosis factor α inhibitor (controls). Disease activity was measured with the 28 joint count Disease Activity Score (DAS28), and clinical response with the American College of Rheumatology (ACR) 20% response criteria. Results: At baseline there were no differences in demographic, clinical, and laboratory features between the two groups. After 12 months’ adalimumab treatment, clinical improvement was similar in both groups. More specifically, ACR 20% response criteria were achieved by 18/24 (75%) switchers and by 19/25 (76%) subjects in the control group. Four switchers discontinued the study—two because of adverse events and two because of lack of efficacy, while three control patients discontinued the study—one because of lack of efficacy and two owing to side effects. Conclusion: Adalimumab is a well tolerated and effective treatment for patients with RA, even when infliximab has been discontinued.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd and European League Against Rheumatism</pub><pmid>15975964</pmid><doi>10.1136/ard.2005.039099</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0003-4967 |
| ispartof | Annals of the rheumatic diseases, 2006-02, Vol.65 (2), p.257-260 |
| issn | 0003-4967 1468-2060 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1798023 |
| source | MEDLINE; BMJ Journals - NESLi2; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | 28 joint count Disease Activity Score ACR Adalimumab Age Aged American College of Rheumatology Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Antirheumatic Agents - administration & dosage Antirheumatic Agents - adverse effects Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - drug therapy Arthritis, Rheumatoid - immunology Arthritis, Rheumatoid - physiopathology Biological and medical sciences Blood Sedimentation C-Reactive Protein - analysis Concise Report Crohn's disease DAS 28 Diseases of the osteoarticular system Drug Administration Schedule Drug dosages Female Health Status Indicators Humans Immunomodulators Infliximab Joints - physiopathology Male Medical sciences methotrexate Middle Aged MTX Pharmacology. Drug treatments Platelet Count Rheumatism rheumatoid arthritis TNFα Treatment Outcome Tumor Necrosis Factor-alpha - antagonists & inhibitors tumour necrosis factor α |
| title | Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T18%3A59%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20safety%20of%20switching%20from%20infliximab%20to%20adalimumab:%20a%20comparative%20controlled%20study&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Nikas,%20S%20N&rft.date=2006-02-01&rft.volume=65&rft.issue=2&rft.spage=257&rft.epage=260&rft.pages=257-260&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/ard.2005.039099&rft_dat=%3Cproquest_pubme%3E4008379771%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1777848449&rft_id=info:pmid/15975964&rfr_iscdi=true |